Detalhe da pesquisa
1.
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
BMC Cancer
; 18(1): 106, 2018 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29382302
2.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Clin Transl Oncol
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512450
3.
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
JAMA Oncol
; 9(3): 344-353, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36520426
4.
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC.
Cancers (Basel)
; 14(12)2022 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35740564
5.
Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer.
Clin Transl Oncol
; 24(11): 2241-2249, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35870091
6.
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Oncotarget
; 13: 812-827, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35720977
7.
Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic.
Front Psychol
; 12: 755965, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34803837
8.
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
Cancer Med
; 10(17): 5878-5888, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34296539
9.
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study.
Lung Cancer Manag
; 10(4): LMT53, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34899993
10.
A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy.
J Immunother Cancer
; 8(2)2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900863
11.
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.
Oncoimmunology
; 9(1): 1751548, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32363123
12.
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Clin Lung Cancer
; 21(5): 428-436.e2, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461037
13.
Nivolumab-induced thyroid dysfunction in patients with lung cancer.
Endocrinol Diabetes Nutr (Engl Ed)
; 66(1): 26-34, 2019 Jan.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-29910159
14.
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Lung Cancer
; 134: 72-78, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31319999
15.
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Transl Lung Cancer Res
; 2(3): 244-50, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25806238
16.
Excess weight and anti-PD-1 immune checkpoint inhibitors outcomes in non-small cell lung cancer
Clin. transl. oncol. (Print)
; 24(11): 2241-2249, noviembre 2022.
Artigo
em Inglês
| IBECS (Espanha) | ID: ibc-210152
17.
Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Clin Cancer Res
; 16(10): 2872-80, 2010 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20460481
18.
Nivolumab-induced thyroid dysfunction in patients with lung cancer / Disfunción Tiroidea Inducida Por Nivolumab En Pacientes Con Cáncer
Endocrinol. diabetes nutr. (Ed. impr.)
; 66(1): 26-34, ene. 2019. tab, graf
Artigo
em Inglês
| IBECS (Espanha) | ID: ibc-175790